| Followers | 5 |
| Posts | 1540 |
| Boards Moderated | 0 |
| Alias Born | 01/29/2022 |
Monday, April 28, 2025 10:26:47 AM
These are the seasoned experienced old sewage fat rat scavengers known for all the tricks of the fraud trade to funnel the cash cow strait in their pockets while they FTW with no share ownership..and pretend they are the victims of their own crimes and now are exposed to the world of fraud artists
Thomas Fitzgerald
74 year
Chief Administrative Officer 2018-06-30
Chief Executive Officer 2024-01-12
Director of Finance/CFO 2018-06-30
President 2024-01-12
Daniel R. Vlock
73 year
Chief Tech/Sci/R&D Officer 2024-03-27
Composition of the Board of Directors: TransCode Therapeutics, Inc.
Director
Committees
Philippe Calais
66 year
Compensation Committee 2021-02-17
Audit Committee Chair 2021-02-17
Magda Marquet
66 year
Audit Committee 2020-12-31
Executive Committee 2018-05-26
Governance Committee 2021-05-31
Nominating Committee 2021-05-31
Compensation Committee Chair 2021-05-31
Thomas Fitzgerald
74 year
Chief Administrative Officer 2018-06-30
Chief Executive Officer 2024-01-12
Director of Finance/CFO 2018-06-30
President 2024-01-12
Daniel R. Vlock
73 year
Chief Tech/Sci/R&D Officer 2024-03-27
Composition of the Board of Directors: TransCode Therapeutics, Inc.
Director
Committees
Philippe Calais
66 year
Compensation Committee 2021-02-17
Audit Committee Chair 2021-02-17
Magda Marquet
66 year
Audit Committee 2020-12-31
Executive Committee 2018-05-26
Governance Committee 2021-05-31
Nominating Committee 2021-05-31
Compensation Committee Chair 2021-05-31
Recent RNAZ News
- TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer • PR Newswire (US) • 05/27/2026 12:04:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/26/2026 10:46:35 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/26/2026 10:43:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:15:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2026 04:15:17 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/08/2026 09:20:58 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/30/2026 09:24:06 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:15:15 PM
- TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University • PR Newswire (US) • 04/27/2026 12:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:17:42 PM
- TransCode Therapeutics signs financing deal worth up to $20 million • IH Market News • 04/07/2026 01:51:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 12:37:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:16 PM
- TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 • PR Newswire (US) • 04/07/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/03/2026 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:39 PM
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Pa • PR Newswire (US) • 03/03/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:10:39 PM
- TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development • PR Newswire (US) • 02/23/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:10:42 PM
- TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 • PR Newswire (US) • 02/05/2026 01:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
- TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma • PR Newswire (US) • 01/06/2026 01:01:00 PM
